Aurobindo Pharma’s arm gets warning letter from USFDA for Unit-III

16 Aug 2024 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-III, a Formulation manufacturing facility has received a Warning Letter from United States Food and Drug Administration (USFDA). There is no impact on the existing supplies to the US markets. 

In May 2024, USFDA had determined the inspection classification status to Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ unit III, formulation manufacturing facility as ‘Official Action Indicated (OAI)’.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1199.00 -6.95 (-0.58%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×